Atlantic Technology Ventures to be Featured On Upcoming Episode of ''Healthy Solutions'' National Television Series.Business Editors/Health & Medical Writers NEW YORK--(BW HealthWire)--Aug. 28, 2001 Atlantic Technology Ventures, Inc. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB: ATLC ATLC Arbitrary Transmission Line Calculator ATLC Atomic Trades and Labor Council ATLC Air Transport Label Catalog ATLC Advanced Technology Licensing Company ) will be featured on an upcoming episode of the "Healthy Solutions" series hosted by Mariette Hartley, scheduled to air as paid programming on CNBC, Saturday, September 1 at 12:00 noon Eastern Time. The show will also air on Saturday, September 1 at 7:30 a.m. and Sunday, September 2 at 7:30 a.m. on the Health Network. The special report entitled, New Hope for Pain and Inflammation, will include Atlantic's development of it's synthetic cannabinoid cannabinoid /can·nab·i·noid/ (kah-nab´i-noid) any of the principles of Cannabis, including tetrahydrocannabinol, cannabinol, and cannabidiol. can·nab·i·noid n. derivative compound, CT-3. Atlantic is developing its proprietary CT-3, a patented synthetic derivative of carboxylic car·box·yl n. The univalent radical, COOH, the functional group characteristic of all organic acids. [carb(o)- + ox(y)- + -yl. tetrahydrocannabinol tetrahydrocannabinol /tet·ra·hy·dro·can·nab·i·nol/ (THC) (-hi?dro-kah-nab´i-nol) the active principle of cannabis, occurring in two isomeric forms, both considered psychomimetically active. (THC-7C), as an alternative to NSAIDs. Preliminary cellular and animal studies have shown that CT-3 demonstrates analgesic and anti-inflammatory properties at microgram microgram /mi·cro·gram/ (µg) (mi´kro-gram) one millionth (10-6) of a gram. mi·cro·gram n. Abbr. doses without central nervous system of gastrointestinal side effects. This makes the compound an attractive development candidate as an analgesic and anti-inflammatory agent with the potential to overcome the major side effects of current anti-inflammatory drugs. CT-3 has successfully completed a phase I clinical trial Noun 1. phase I clinical trial - a clinical trial on a few persons to determine the safety of a new drug or invasive medical device; for drugs, dosage or toxicity limits should be obtained phase I and is entering several phase II clinical trials for multiple indications. Atlantic Technology Ventures, Inc. Atlantic Technology Ventures, Inc. is a publicly held venture capital company specializing in early-stage, breakthrough technologies and rapidly incubating these through a definitive proof-of-principle. Atlantic currently has investments in: Catarex, a device for cataract removal; CT-3, a synthetic derivative of marijuana for treating pain and inflammation; and superconducting electronics for telecommunications. Safe Harbor Statement Cautionary statement under the "safe harbor" provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: This press release contains certain forward-looking statements that relate to future scientific, business and financial performance. These statements are only predictions and are subject to a number of risks and uncertainties that may cause the actual events or results to differ from those discussed or implied in these statements. These risks and uncertainties include competition from other manufacturers of related technologies, the unavailability of any necessary intellectual property rights possessed by third parties, and certain of those risks described in Atlantic's most recent report on Form 10-KSB with the Securities and Exchange Commission. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion